Khang & Khang LLP (the “Firm”) announces that it is investigating claims against United Therapeutics Corporation (“United Therapeutics” or the “Company”) (Nasdaq: UTHR) concerning possible violations of federal securities laws.
If you purchased shares of United Therapeutics and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250 Irvine, CA 92604, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
The investigation concerns whether United Therapeutics and certain of its officers and/or directors violated federal securities laws. On July 27, 2017, the Company revealed that it recorded a $210 million accrual relating to a potential settlement in connection with a Department of Justice investigation into the Company’s possible violations of the Federal Anti-Kickback Statute and the Federal False Claims Act. When this news was announced, shares of United Therapeutics fell in value.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170727006704/en/
Contacts:
Joon M. Khang, Esq.
Telephone:
949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
